Datatruck | $12,000,000 | (Jan 29, 2026)
Vention | $110,000,000 | (Jan 29, 2026)
Tenbin Labs | $7,000,000 | (Jan 29, 2026)
Certified by Founder
Lodge
Braveheart Bio
start up
United States
- San Francisco, California
- 06/11/2025
- Series A
- $185,000,000
Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science investors including Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital), and Frazier Life Sciences. Braveheart is advancing BHB-1893 through late-stage clinical development with the goal of establishing a new standard of care.
- Industry Biotechnology Research
- Website https://www.braveheart.bio/
- LinkedIn https://www.linkedin.com/company/braveheart-bio/
Oro(US) | $3,000,000 | (Jan 29, 2026)
Yolando | $8,500,000 | (Jan 29, 2026)
Origin(US) | Undisclosed Amount | (Jan 29, 2026)
Gyde | $60,000,000 | (Jan 29, 2026)
Limy AI | $10,000,000 | (Jan 29, 2026)
Scholé AI | $3,000,000 | (Jan 29, 2026)
Emobi | $3,400,000 | (Jan 29, 2026)
Adaptive6 | $28,000,000 | (Jan 29, 2026)
Fiddler AI | $30,000,000 | (Jan 28, 2026)